Head and neck cancer

Mody, Mayur D.; Rocco, James W.; Yom, Sue S.; Haddad, Robert I.; Saba, Nabil F.

doi:10.1016/s0140-6736(21)01550-6

Cited by 496 publications

(403 citation statements)

References 112 publications

Supporting

Mentioning

392

Contrasting

Unclassified

Order By: Relevance

“…The High-risk types, i.e., HPV 16,18,31,33,35,39,45,51,52,56,58 and 59, have a distinctive oncogenic potential, being the aetiological agents of cervical, vulvar, vaginal, penile, and a subset of head and neck squamous cell carcinoma (HNSCC) [10]. In particular, HPV has a predominant role in the development of oropharyngeal squamous cell carcinoma (OPSCC) [11,12].…”

Section: Introductionmentioning

confidence: 99%

Human Papillomavirus Oral Infection: Review of Methodological Aspects and Epidemiology

et al. 2021

View full text Add to dashboard Cite

Oral infection by Human Papillomavirus (HPV) has recently gained great attention because of its involvement in the development of a subset of head and neck squamous cell carcinoma. The role of specific Alpha-HPVs in this regard has been well established, whereas the contribution of other genera is under investigation. Despite their traditional classification as “cutaneous” types, Beta and Gamma HPVs are frequently detected in oral samples. Due to the lack of a standardized protocol, a large variety of methodologies have been used for oral sample collection, DNA extraction, HPV detection and genotyping. Laboratory procedures influence the evaluation of oral HPV prevalence, which largely varies also according to the population characteristics, e.g., age, gender, sexual behavior, Human Immunodeficiency Virus (HIV) status. Nevertheless, oral infection by Beta and Gamma HPVs seems to be even more common than Alpha-HPVs. The latter is 5–7% in the general population, and increases up to 30% approximately in HIV-infected men who have sex with men. Despite major advances in the evaluation of oral HPV prevalence, its natural history is still little understood, especially for Beta and Gamma HPVs. The latest technologies, such as Next Generation Sequencing (NGS), can be exploited to gain new insights into oral HPV, and to improve the identification of novel HPV types.

show abstract

Section: Introductionmentioning

confidence: 99%

Human Papillomavirus Oral Infection: Review of Methodological Aspects and Epidemiology

et al. 2021

View full text Add to dashboard Cite

show abstract

“…No reuse allowed without permission. metastatic spread (26,27,31). To model this preclinically, we developed a neck dissection surgery in the mouse, informed by our cervical lymphatic mapping (Fig.…”

Section: Murine Neck Dissection Modelmentioning

confidence: 99%

“…No reuse allowed without permission. therapy (26); and, standard of care management for HNSCC patients with regional metastatic disease necessarily entails either primary surgical or radiation therapy for both involved and uninvolved draining lymph nodes (2,27). Accordingly, we noted that the landmark clinical trials defining how we currently employ IO therapy in HNSCC necessarily recruited patients who have contemporaneously or previously received ablative locoregional therapies, which prompted us to explore whether this may negatively affect host immunity and the tumor response to ICI.…”

Section: Introductionmentioning

confidence: 99%

Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC

Saddawi‐Konefka

O’Farrell

Faraji

et al. 2022

Preprint

View full text Add to dashboard Cite

Immune checkpoint inhibition (ICI) with anti-CTLA-4 and anti-PD-1 has revolutionized oncology; however, response rates remain limited in most cancer types, highlighting the need for more effective immune oncology (IO) treatment strategies. Paradoxically, head and neck squamous cell carcinoma (HNSCC), which bears a mutational burden and immune infiltrate commensurate with cancers that respond robustly to ICI, has demonstrated no response to anti-CTLA-4 in any setting or to anti-PD-1 for locally-advanced disease. Scrutiny of the landmark clinical trials defining current IO treatments in HNSCC reveals that recruited patients necessarily received regional ablative therapies per standard of care, prompting us to hypothesize that standard therapies, which by design ablate locoregional lymphatics, may compromise host immunity and the tumor response to ICI. To address this, we employed tobacco-signature HNSCC murine models in which we mapped tumor-draining lymphatics and developed models for regional lymphablation with surgery or radiation. Remarkably, we found that lymphablation eliminates the tumor ICI response, significantly worsening overall survival and repolarizing the tumor- and peripheral-immune compartments. Mechanistically, within tumor-draining lymphatics, we observed an upregulation of cDC1 cells and IFN-I signaling, showed that both are necessary for the ICI response and lost with lymphablation. Ultimately, we defined rational IO sequences that mobilize peripheral immunity, achieve optimal tumor responses, confer durable immunity and control regional lymphatic metastasis. In sum, we provide a mechanistic understanding of how standard regional, lymphablative therapies impact the response to ICI, which affords insights that can be applied to define rational, lymphatic-preserving IO treatment sequences for cancer.

show abstract

“…Head and neck cancer (HNC) is the seventh most common type of cancer worldwide [ 1 ]. HNC represents a diverse group of tumor entities covering several anatomical subsites in the upper aerodigestive region.…”

Section: Introductionmentioning

confidence: 99%

“…About half of the patients are still diagnosed at advanced stage [ 2 , 3 ]. In most cases, a monotherapeutic approach (surgery alone or radiotherapy alone) is used for early-stage disease, whereas locally-advanced stages are treated by multimodal approaches [ 1 , 4 , 5 ]. Chemotherapy/immunotherapy regimens are mainly part of concurrent or postoperative radiochemotherapy/immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

Trends in Treatment of Head and Neck Cancer in Germany: A Diagnosis-Related-Groups-Based Nationwide Analysis, 2005–2018

Hermanns

Ziadat

Guntinas‐Lichius

2021

Cancers

View full text Add to dashboard Cite

Advances in head and neck cancer (HNC) treatment might have changed treatment strategies. This study determined, with focus on gender disparity, whether treatment rates have changed for inpatients in Germany between 2005 and 2018. Nation-wide population-based diagnosis-related groups (DRG) data of virtually all HNC cases (1,226,856 procedures; 78% men) were evaluated. Poisson regression analyses were used to study changes of annual treatment rates per German population. For surgery, the highest increase was seen for women with cancer of the oral cavity (relative risk (RR) 1.14, 95% confidence interval (CI) 1.11–1.18, p < 0.0001) and the highest decrease for men with laryngeal cancer (RR 0.90, CI 0.87–0.93). In women with oropharyngeal cancer, the highest increase of radiotherapy rates was seen (RR 1.18, CI 1.10–1.27, p < 0.0001). A decrease was seen in men for hypopharyngeal cancer (RR 0.93, CI 0.87–0.98, p = 0.0093). The highest increase for chemotherapy/immunotherapy was seen for women with oropharyngeal cancer (RR 1.16, CI 1.08–1.24, p < 0.0001), and a decrease in men with hypopharyngeal cancer (RR 0.93, CI 0.88–0.97, p = 0.0014). Treatment patterns had changed for nearly all subsites and therapy types. There were relevant gender disparities, which cannot be explained by the DRG data.

show abstract

Head and neck cancer

Cited by 496 publications

References 112 publications

Human Papillomavirus Oral Infection: Review of Methodological Aspects and Epidemiology

Human Papillomavirus Oral Infection: Review of Methodological Aspects and Epidemiology

Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC

Trends in Treatment of Head and Neck Cancer in Germany: A Diagnosis-Related-Groups-Based Nationwide Analysis, 2005–2018

Contact Info

Product

Resources

About